FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Genentech's Enspryng Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
Golconda Gold Announces the Election of Paul Olmsted and James Colter Eadie to the Board of Directors
Standard Uranium Initiates 2026 Drill Program at the Davidson River Uranium Project, Southwest Athabasca Basin
Nuvau Minerals commences PEA study to advance Matagami restart strategy, which includes a fully permitted critical metals mine
